Combining tesofensine and GLP-1 agonists for weight loss isn't currently recommended due to potential safety concerns and lack of sufficient research on their combined effects
Investigado y verificado con Liquilabs s.r.o
Another candidate developed through this platform includes a dual GIP/GLP-1 gene therapy to treat obesity, currently in preclinical development
Persistent nausea beyond four weeks may indicate underlying gallbladder dysfunction or bile acid malabsorption, which requires prescriber evaluation
Many patients report that headaches diminish or resolve completely after the first month of therapy, suggesting an adaptation effect
Vidal-Casariego A, Burgos-Pelez R, Martnez-Faedo C, Calvo-Gracia F, Valero-Zanuy M, Luengo-Prez LM, Cuerda-Comps C